STOP PRESS: Glaxo diabetes drug withdrawn from sale

Following the withdrawal of Glaxo Wellcome’s newest diabetes drug Romozin (troglitazone), the PR campaign being run by Manning Selvage and Lee has been suspended. Glaxo withdrew the drug after an increase in liver problems was identified among users. Around 5,000 people in the UK have been prescribed the drug since its launch two months ago. Glaxo is handling crisis PR in-house.

by JULIETTE GARSIDE

Sign in to continue

Sign in

Sign in

Trouble signing in?

Reset password: Click here

US and Asia
subscriptions@prweek.com
+001 (800) 558-1708

UK & Europe
support@prweek.com
+44 (0)20 8267 8121

Register

Don't have an account? Complete easy registration and receive:

  • Limited Article Views (Excludes Subscriber Only Content)
  • Select Newsletters (Excludes Subscriber Only Bulletins)

Register Now

Register

FREE

  • Limited free articles a month
  • Limited number of free email bulletins

Register Now

Subscribe

To receive full access to PRWeek's content subscribe today and receive:

  • Unrestricted individual access to prweek.com
  • Breaking news and industry updates via PRWeek Daily News bulletin
  • Exclusive access to Agency Business Report, annual Salary Survey, Power List, 40 Under 40, & Best Places to Work, and more

Subscribe Options

Start your free trial 

Enjoy these subscriber-exclusive benefits:

  • Unrestricted individual access to prweek.com
  • Breaking news and industry updates via PRWeek Daily News bulletin
  • Exclusive access to Power Book and Top 150 UK Agency Business Report

Join today

Need to activate your subscription?

Domain/Group Subscriptions
Click here >>

Individual Subscriptions
Click here >>

Need to activate your Subscription

Company Wide Subscriptions
Click here >>

 UK Individual Subscribers
Click here >>